165 related articles for article (PubMed ID: 28086032)
1. Liver injury associated with dimethyl fumarate in multiple sclerosis patients.
Muñoz MA; Kulick CG; Kortepeter CM; Levin RL; Avigan MI
Mult Scler; 2017 Dec; 23(14):1947-1949. PubMed ID: 28086032
[TBL] [Abstract][Full Text] [Related]
2. Severe drug-induced liver injury related to therapy with dimethyl fumarate.
Jüngst C; Kim YJ; Lammert F
Hepatology; 2016 Oct; 64(4):1367-9. PubMed ID: 27228386
[No Abstract] [Full Text] [Related]
3. Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
Zecca C; Antozzi CG; Torri Clerici V; Ferrazzini M; Mantegazza RE; Rossi S; Gobbi C
Acta Neurol Scand; 2018 Jun; 137(6):623-625. PubMed ID: 29205270
[TBL] [Abstract][Full Text] [Related]
4. Dimethyl fumarate induced migrating polyarthralgias.
Villedon de Naide M; Moisset X; Soubrier M
Joint Bone Spine; 2019 May; 86(3):399-400. PubMed ID: 30081200
[No Abstract] [Full Text] [Related]
5. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
[TBL] [Abstract][Full Text] [Related]
6. Clinically significant liver injury in patients treated with natalizumab.
Bezabeh S; Flowers CM; Kortepeter C; Avigan M
Aliment Pharmacol Ther; 2010 May; 31(9):1028-35. PubMed ID: 20163378
[TBL] [Abstract][Full Text] [Related]
7. Dimethyl fumarate in a patient with multiple sclerosis and type 1 diabetes mellitus: The importance of ketonuria.
Krzystanek E; Jarosz-Chobot P
Mult Scler Relat Disord; 2018 Apr; 21():42-45. PubMed ID: 29455073
[TBL] [Abstract][Full Text] [Related]
8. Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate.
O'Gorman J; Russell HK; Li J; Phillips G; Kurukulasuriya NC; Viglietta V
Clin Ther; 2015 Jul; 37(7):1402-1419.e5. PubMed ID: 25999183
[TBL] [Abstract][Full Text] [Related]
9. Severe articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosis.
Bernardini LR; Zecca C; Clerici VT; Gobbi C; Mantegazza R; Rossi S
J Neurol Sci; 2016 Oct; 369():139-140. PubMed ID: 27653880
[No Abstract] [Full Text] [Related]
10. Delayed lymphocyte re-population following discontinuation of dimethyl fumarate and after switching to other disease modifying drug therapies.
Khatri BO; Tarima SS; Essig B; Sesing J; Olapo T
Mult Scler Relat Disord; 2017 Nov; 18():60-64. PubMed ID: 29141823
[TBL] [Abstract][Full Text] [Related]
11. Erythema nodosum in a patient with multiple sclerosis on dimethyl fumarate.
Algahtani H; Shirah B; Marghalani S; Algarni A
Mult Scler Relat Disord; 2019 Feb; 28():155-158. PubMed ID: 30597324
[TBL] [Abstract][Full Text] [Related]
12. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L
Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150
[TBL] [Abstract][Full Text] [Related]
13. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
Fleischer V; Friedrich M; Rezk A; Bühler U; Witsch E; Uphaus T; Bittner S; Groppa S; Tackenberg B; Bar-Or A; Zipp F; Luessi F
Mult Scler; 2018 Apr; 24(5):632-641. PubMed ID: 28436295
[TBL] [Abstract][Full Text] [Related]
14. Effects of dimethyl fumarate on lymphocyte subsets.
Berkovich R; Weiner LP
Mult Scler Relat Disord; 2015 Jul; 4(4):339-41. PubMed ID: 26195053
[TBL] [Abstract][Full Text] [Related]
15. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study.
Mallucci G; Annovazzi P; Miante S; Torri-Clerici V; Matta M; La Gioia S; Cavarretta R; Mantero V; Costantini G; D'Ambrosio V; Zaffaroni M; Ghezzi A; Perini P; Rossi S; Bertolotto A; Rottoli MR; Rovaris M; Balgera R; Cavalla P; Montomoli C; Bergamaschi R
J Neurol; 2018 Aug; 265(8):1850-1859. PubMed ID: 29948245
[TBL] [Abstract][Full Text] [Related]
16. Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate.
Purchiaroni F; Salvetti M; Buscarinu MC; Annibale B
Neurology; 2016 Aug; 87(9):952-3. PubMed ID: 27466473
[No Abstract] [Full Text] [Related]
17. Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis.
Gelibter S; Orrico M; Moiola L; Dagna L; Filippi M; Yacoub MR
J Neurol Sci; 2020 Nov; 418():117104. PubMed ID: 32871512
[No Abstract] [Full Text] [Related]
18. Oral Dimethyl Fumarate in Children With Multiple Sclerosis: A Dual-Center Study.
Makhani N; Schreiner T
Pediatr Neurol; 2016 Apr; 57():101-4. PubMed ID: 26996405
[TBL] [Abstract][Full Text] [Related]
19. Diffuse dermatophytosis occurring on dimethyl fumarate therapy.
Greenstein JI
Mult Scler; 2018 Jun; 24(7):999-1001. PubMed ID: 29649923
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
